MannKind Corp MNKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MNKD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.16
- Day Range
- $4.15–4.29
- 52-Week Range
- $3.17–5.75
- Bid/Ask
- $4.17 / $4.22
- Market Cap
- $1.13 Bil
- Volume/Avg
- 2.2 Mil / 3.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 1,776.93
- Price/Sales
- 5.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 414
- Website
- https://www.mannkindcorp.com
Comparables
Valuation
|
Metric
|
MNKD
|
NBIX
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | 1,776.93 | 28.06 | — |
Price/Book Value | — | 6.19 | 0.56 |
Price/Sales | 5.62 | 7.50 | — |
Price/Cash Flow | 57.47 | 39.12 | — |
Price/Earnings
MNKD
NBIX
AVIR
Financial Strength
|
Metric
|
MNKD
|
NBIX
|
AVIR
|
|---|---|---|---|
Quick Ratio | 2.98 | 2.25 | 17.86 |
Current Ratio | 3.59 | 2.45 | 18.24 |
Interest Coverage | 0.34 | 73.20 | — |
Quick Ratio
MNKD
NBIX
AVIR
Profitability
|
Metric
|
MNKD
|
NBIX
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | 1.73% | 14.51% | −15.46% |
Return on Equity (Normalized) | — | 20.57% | −16.16% |
Return on Invested Capital (Normalized) | 85.26% | 17.92% | −19.92% |
Return on Assets
MNKD
NBIX
AVIR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ctsfnmbryv | Mnr | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cngzwrhm | Kntmmj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hgjwgcbsz | Fpybzfx | $99.5 Bil | |
MRNA
| Moderna Inc | Wbblrqkdl | Gjsnn | $38.8 Bil | |
ARGX
| argenx SE ADR | Tjqlmyxq | Bmjp | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Bsplwdmj | Rgh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zzwtmskjn | Dsfcnh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ywbjmqkh | Bkdsvv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ytrzmgwd | Xphmfr | $12.5 Bil | |
INCY
| Incyte Corp | Hwfmjnmgr | Kfvvtlg | $11.6 Bil |